Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 4/20 | 0.30 |
| ▸ | KMO | O15229 | 2/20 | 0.30 |
| ▸ | BMX | P51813 | 2/20 | 0.30 |
| ▸ | ITK | Q08881 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29333551 | 1.00 | BTK (0.32) | BTKLMNAPOLBHTTHSD17B10 | |
| SCHEMBL29333545 | 0.90 | MAPK1 (0.33) | BTKCCNCCDK8MAPK1EGFR | |
| SCHEMBL29333526 | 0.86 | KMO (0.39) | BTKCCNCCDK8MAPK1EGFR | |
| SCHEMBL31008633 | 0.86 | KMO (0.39) | BTKCCNCCDK8MAPK1EGFR | |
| SCHEMBL29333557 | 0.85 | EGFR (0.32) | CCNCCDK8EGFRKMO | |
| SCHEMBL31008595 | 0.85 | EGFR (0.32) | CCNCCDK8EGFRKMO | |
| SCHEMBL29333578 | 0.84 | MAPK1 (0.35) | CCNCCDK8MAPK1 | |
| SCHEMBL29334354 | 0.84 | CCNC (0.38) | BTKCCNCCDK8MAPK1EGFR | |
| SCHEMBL29333690 | 0.81 | KRAS (0.32) | KMO | |
| SCHEMBL29336018 | 0.81 | KRAS (0.32) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | BTK 3290/4885LMNA 1176/4885POLB 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.